Loading…
Loading…
SSKN does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SSKN and 80,000+ other tickers.
See exactly how SSKN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SSKN and 80,000+ other tickers.
STRATA Skin Sciences, Inc. is an innovative medical technology enterprise dedicated to the development, commercialization, and marketing of advanced products specifically designed for treating a range of dermatologic conditions. The company operates through two main divisions: Dermatology Recurring Procedures and Dermatology Procedures Equipment. With a substantial global footprint, STRATA Skin Sciences distributes its solutions across the United States, Europe, the Middle East, Asia, Australia, South Africa, and both Central and South America. Its notable product portfolio includes the XTRAC…
Medical device veteran poised to lead STRATA to market leadership and continued revenue growth as Company continues next development phase Medical device veteran poised to lead STRATA to market leadership and continued revenue growth as Company continues next development phase
Multicenter prospective RCT published in JAAD confirms superiority of XTRAC® Excimer Laser plus oral JAK inhibitors over tacrolimus combination therapy in children aged 2–18 years with progressive vitiligo, fueling continued market growth and expanding indications Multicenter prospective RCT published in JAAD confirms superiority of XTRAC® Excimer Laser plus oral JAK inhibitors over tacrolimus combination therapy in children aged 2–18 years with progressive vitiligo, fueling continued market growth and expanding indications
Strata Skin Sciences, Inc. (NASDAQ: SSKN - Get Free Report) was the target of a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 679,358 shares, an increase of 89.2% from the January 29th total of 358,994 shares. Currently, 19.5% of the company's shares are sold
Strata Skin Sciences (NASDAQ: SSKN - Get Free Report) and Hims and Hers Health (NYSE: HIMS - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings. Institutional and Insider Ownership 32.4%
Strata Skin Sciences (NASDAQ: SSKN - Get Free Report) and Clover Health Investments (NASDAQ: CLOV - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Institutional and Insider Ownership 32.4%